InDex Pharmaceuticals published the interim report for Q2 2023 on August 23, 2023.

Our phase III program CONCLUDE

Have a look at InDex’s corporate presentation

CEO corner

Learn more about Jenny Sundqvist, our CEO

InDex Pharmaceuticals is developing cobitolimod for treatment of moderate to severe left-sided ulcerative colitis

Proud partner of: